Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2022 - 02 - 14 crawled time : 23:00 save search
Largest Hospital in Queensland, Australia Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
ARAY | $2.2 -0.9% -0.91% 290K
|
Health Technology
|
| O: -6.17%
H: 6.38%
C: 2.47%
radixact imaging system australia
SunOpta Inc. Schedules Fourth Quarter and Full Year 2021 Financial Results Release and Conference Call
Published: 2022-02-14 (Crawled : 23:00) - sunopta.com
STKL A | $5.94 -1.66% -1.68% 1.8M
|
Consumer Non-Durables
|
| O: 1.21%
H: 0.0%
C: -4.37%
financial results conference results
1-800-FLOWERS.COM, Inc. Leverages the Snowflake Data Cloud to Help People Send Love
Published: 2022-02-14 (Crawled : 23:00) - snowflake.com
SNOW | $154.99 2.53% -1.32% 3.9M
|
Technology Services
|
| O: 2.64%
H: 1.06%
C: 0.39%
FLWS 4 | $9.25 -0.11% -0.11% 250K
|
Retail Trade
|
| O: 0.51%
H: 3.97%
C: 3.51%
PROCEPT Announces 5-Year WATER Study Data Comparing Aquablation to TURP
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
PRCT A | $52.51 -2.31% -2.36% 520K
|
Manufacturing
|
| O: 0.35%
H: 2.1%
C: -0.15%
ces
25 Modern Logo Design Examples and Ideas to Energize and Inspire
Published: 2022-02-14 (Crawled : 23:00) - shutterstock.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
designation
Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
XENE | $39.46 -3.97% -4.13% 330K
|
Health Technology
|
| O: 0.72%
H: 1.88%
C: -0.58%
health als thc conference svb leerink global
Omnicom Scores Big in USA TODAY’s 34th Annual Ad Meter Competition for Super Bowl LVI Ads
Published: 2022-02-14 (Crawled : 23:00) - omnicomgroup.com
OMC | $95.98 1.87% 0.0% 2.2M
|
Commercial Services
|
| O: 1.13%
H: 1.4%
C: 0.84%
day oda
Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: -3.44%
H: 2.07%
C: -7.82%
covid-19 health covid authorization vaccine
ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer
Published: 2022-02-14 (Crawled : 23:00) - nantkwest.com
IBRX | $4.815 -12.3% -14.02% 7.9M
|
Manufacturing
|
| O: 9.91%
H: 12.66%
C: 11.23%
bladder cancer media 100 pons cancer set bladder
STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
SSKN | $0.549 1.67% 1.64% 5.6K
|
Health Technology
|
| O: -1.32%
H: 4.03%
C: -0.67%
ces skin
Katy’s Korner: Do We Really Need to Travel During A Pandemic?
Published: 2022-02-14 (Crawled : 23:00) - extremenetworks.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: 3.72%
H: 3.08%
C: 2.56%
EXTR 4 | $11.155 0.59% 0.58% 1.6M
|
Electronic Technology
|
| O: 1.59%
H: 3.7%
C: 3.54%
travel
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 1.38%
H: 0.51%
C: -5.11%
financial results therapeutics results
LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
lynparza risk prostate cancer state disease one cancer
LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.01%
H: 0.09%
C: -0.21%
lynparza risk prostate cancer state disease one cancer biomarkers
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.27%
H: 0.2%
C: 0.0%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.01%
H: 0.22%
C: -0.09%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: -0.27%
H: 1.12%
C: -0.59%
opdivo renal trial cel cell carcinoma nivolumab
MMAT INVESTORS: Levi & Korsinsky, LLP Reminds Shareholders of Meta Materials Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 4, 2022
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
MMAT | $3.14 7.17% 6.69% 310K
|
Mining, Quarrying, and Oil and ...
|
| O: 2.23%
H: 8.2%
C: 7.65%
als deadline rmat
EPIC DEAL TO COMBAT WOES OF EPIC LINES
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
deal
Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.32%
H: 1.19%
C: 0.71%
prostate cancer state one therapy cancer
New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.32%
H: 1.19%
C: 0.71%
erleada prostate cancer state response pons cancer
Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® (betaine anhydrous for oral solution) Powder, Including 180 Days of Exclusivity
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
ANIP S | $65.375 -1.16% -1.17% 83K
|
Health Technology
|
| O: 1.28%
H: 2.13%
C: 1.92%
cystadane day als
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.